TAK-448

DRACPC ID  DRACPC0073

Active Ingredients   TAK-448

Description  A metastin/kisspeptin analog consisting of nine amino acids, have an anti-tumor effect through suppression of androgen hormones (luteinizing hormone and testosterone) levels. Kisspeptin/metastin, a hypothalamic peptide, plays a pivotal role in controlling gonadotropin-releasing hormone (GnRH) neurons.

Synonyms  TAK 448; TAK448; RVT-602; 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide monoacetate; TAK-448

Type  Small Molecule

Disease  Prostate Cancer, Low Testosterone

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  C58H80N16O14

Molecular Weight  1225.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide

InChI  InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1

InChI_Key MWXWMWSUUYXMRA-GRKBUMBKSA-N

SMILES  NC(C[C@H](NC([C@]1([H])C[C@@H](O)CN1C([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)=O)C(N[C@@H]([C@H](O)C)C(N[C@H](C(NNC(N[C@H](C(N[C@@H](CCCNC(NC)=N)C(N[C@H](C(N)=O)CC3=CNC4=C3C=CC=C4)=O)=O)CC(C)C)=O)=O)CC5=CC=CC=C5)=O)=O)=O

External Codes


PubChem CID  46700761

DrugBank Accession Number  DB11975

NCI Thesaurus Code  Not available

UNII  YO029HR229   GSRS

CAS  1234319-68-6



Drug approval


Drug indication
    TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT02369796 An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism Hypogonadotropic Hypogonadism Phase 2 Treatment
NCT02381288 A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone Low Testosterone Phase 2 Treatment
NCT01132404 A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin Prostate Cancer; Prostatic Neoplasms Phase 1/2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.